تخطى إلى المحتوى / Skip to content
Clinical Reference Hub

Perinatal Depression

Depression occurring during pregnancy or in the first year postpartum, affecting maternal and infant health.

Medical disclaimer: This page is an educational clinical-decision-support reference for licensed healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. If you are a patient with symptoms, consult a qualified physician. Always verify dosing and guidance against current clinical guidelines and the cited references.

🩺What is Perinatal Depression?

The Edinburgh Postnatal Depression Scale (EPDS) was developed by Cox, Holden, and Sagovsky in 1987 at the University of Edinburgh. It is a 10-item self-report scale that assesses depressive symptoms over the past 7 days. Each item is scored 0-3, yielding a total score of 0-30. The EPDS has been validated in over 60 languages and across diverse populations worldwide. It is the most widely used screening instrument for postpartum depression and is recommended by the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), and the US Preventive Services Task Force (USPSTF). A cutoff of ≥10 indicates possible depression, while ≥13 indicates probable depression of varying severity. Item 10 screens for self-harm thoughts and requires immediate attention regardless of total score.

ICD-10 Classification Code:F53

🏥Signs & Symptoms

The following clinical signs and symptoms are commonly assessed when evaluating Perinatal Depression:

  • I have been able to laugh and see the funny side of things
  • I have looked forward with enjoyment to things
  • I have blamed myself unnecessarily when things went wrong
  • I have been anxious or worried for no good reason
  • I have felt scared or panicky for no very good reason
  • Things have been getting on top of me
  • I have been so unhappy that I have had difficulty sleeping
  • I have felt sad or miserable
  • I have been so unhappy that I have been crying
  • The thought of harming myself has occurred to me

🔬Causes & Etiology

The Edinburgh Postnatal Depression Scale (EPDS) was developed by Cox, Holden, and Sagovsky in 1987 at the University of Edinburgh. It is a 10-item self-report scale that assesses depressive symptoms over the past 7 days. Each item is scored 0-3, yielding a total score of 0-30. The EPDS has been validated in over 60 languages and across diverse populations worldwide. It is the most widely used screening instrument for postpartum depression and is recommended by the American College of Obstetricians and Gynecologists (ACOG), the National Institute for Health and Care Excellence (NICE), and the US Preventive Services Task Force (USPSTF). A cutoff of ≥10 indicates possible depression, while ≥13 indicates probable depression of varying severity. Item 10 screens for self-harm thoughts and requires immediate attention regardless of total score.

📊Clinical Assessment & Risk Scoring

Healthcare professionals use these validated clinical calculators, diagnostic scales, and risk scoring systems to assess the severity, prognosis, or therapeutic dosing requirements for Perinatal Depression:

  • Edinburgh Postnatal Depression Scale (EPDS)

    The Edinburgh Postnatal Depression Scale (EPDS) is a validated 10-item self-report questionnaire designed to screen for postpartum depression in women during the postnatal period. It is widely used in obstetric, midwifery, and primary care settings globally.

🧬Diagnostic Logic & Scoring Breakdown

The EPDS total score is the sum of responses to all 10 questions. Each question is scored 0, 1, 2, or 3 based on the frequency or intensity of symptoms over the past 7 days. The minimum total score is 0 and the maximum is 30. A score of 10 or higher is considered the standard cutoff for a positive screen for possible postpartum depression. A score of 13 or higher suggests probable depression warranting clinical evaluation. Item 10 (self-harm thoughts) must always be reviewed immediately regardless of total score — any score >0 on item 10 requires urgent safety assessment.

📢Clinical Significance & Implications

The Edinburgh Postnatal Depression Scale (EPDS) is the most widely validated and clinically used screening instrument for postpartum depression worldwide. Its clinical significance is supported by extensive research across multiple domains. First, postpartum depression affects 10-15% of new mothers and the EPDS enables early detection, which is critical as untreated postpartum depression has significant consequences for maternal health, child development, and mother-infant bonding. Second, the EPDS has been validated in over 60 languages and across diverse cultural and socioeconomic settings, making it accessible globally. Third, the EPDS includes item 10 which specifically screens for self-harm thoughts, providing a critical safety assessment that is often missed in general depression screening tools. Fourth, the EPDS is recommended by all major clinical guidelines including ACOG, NICE, the USPSTF, and the World Health Organization (WHO). The standard screening protocol recommends administration at the 6-8 week postnatal visit, with repeat screening as clinically indicated. The EPDS takes approximately 5 minutes to complete and is available in both self-report and interviewer-administered formats.

🛡️Prevention & Management

Evidence-based prevention and management strategies for Perinatal Depression include:

  • No immediate action required. Continue routine postnatal care. Re-screen at next visit if concerns persist.
  • Refer for further assessment (CBT, counseling, or psychiatric evaluation). Monitor mood symptoms closely. Schedule follow-up in 1-2 weeks. Rule out hypothyroidism and anemia.
  • Urgent mental health referral indicated. Comprehensive psychiatric assessment recommended. Assess suicide risk and ensure safety plan. Consider pharmacotherapy (SSRIs generally safe in breastfeeding).
  • The EPDS is typically administered at the 6-8 week postpartum check-up, though it can be used at any time during the postnatal period. The USPSTF and ACOG recommend screening for depression in pregnant and postpartum women at least once during the perinatal period. Women with risk factors (history of depression, anxiety, or previous postpartum depression) should be screened earlier and more frequently. The EPDS can also be administered during pregnancy for antenatal depression screening.
  • A cutoff score of ≥10 on the EPDS indicates a positive screen for possible postpartum depression. At this cutoff, the EPDS has a sensitivity of approximately 80% and specificity of approximately 88% for major depressive disorder. Scores of 10-12 suggest possible depression requiring further assessment. Scores of ≥13 indicate probable depression of varying severity and warrant clinical evaluation and intervention. However, clinical judgment should always be used — a woman with a score below 10 but significant clinical concerns should still be evaluated further.
  • Any score >0 on item 10 requires immediate safety assessment. This is a psychiatric emergency. Do not leave the patient alone. Assess current suicidal ideation, plan, intent, means, and protective factors. Ensure immediate psychiatric consultation. Create a safety plan and remove access to lethal means. Arrange for appropriate level of care (outpatient with frequent follow-up, partial hospitalization, or inpatient admission depending on risk level). Inform the patient's partner or family member if clinically appropriate and with consent.

💡 Clinical Assessment Scenario Example

A 29-year-old primiparous woman presents for her 6-week postpartum check-up. She reports difficulty sleeping even when the baby is sleeping, feels tearful most days, and has lost interest in activities she previously enjoyed. She denies thoughts of self-harm. Her EPDS responses are as follows: Q1 (laughter): 1, Q2 (enjoyment): 2, Q3 (self-blame): 1, Q4 (anxiety): 2, Q5 (fear/panic): 0, Q6 (overwhelmed): 2, Q7 (sleep difficulty): 3, Q8 (sadness): 2, Q9 (tearfulness): 2, Q10 (self-harm): 0. Total score = 1 + 2 + 1 + 2 + 0 + 2 + 3 + 2 + 2 + 0 = 15/30. This score falls in the "Probable depression" range (≥13). The clinical recommendation includes urgent mental health referral, comprehensive psychiatric assessment, and consideration of pharmacotherapy (SSRIs which are generally safe in breastfeeding). Close follow-up should be scheduled within 1 week.

💊Common Medications & Interventions

The following pharmacological therapies and substances are commonly referenced or adjusted based on the clinical assessment of Perinatal Depression:

SertralineSSRI
EscitalopramSSRI

⚠️Clinical Assessment Pitfalls

  • Mistake: Using EPDS as a standalone diagnostic tool for postpartum depression

    Correction: EPDS is a screening tool, not a diagnostic instrument. Positive screens (≥10) require comprehensive clinical diagnostic evaluation. A formal diagnosis of postpartum depression requires clinical interview per DSM-5 or ICD-11 criteria.

  • Mistake: Ignoring item 10 (self-harm) if the total score is low

    Correction: Any score >0 on item 10 requires immediate safety assessment regardless of total EPDS score. Self-harm ideation in the postpartum period is a psychiatric emergency requiring urgent evaluation and safety planning.

🚑When to Seek Medical Attention

This reference supports clinical assessment of Perinatal Depression; it does not replace urgent evaluation. Seek prompt in-person medical care if symptoms are severe, rapidly worsening, or life-threatening, or if you are unsure about a diagnosis or treatment plan. Patients should always consult their physician before starting or changing any therapy.

Frequently Asked Questions

Q: When should the EPDS be administered?

The EPDS is typically administered at the 6-8 week postpartum check-up, though it can be used at any time during the postnatal period. The USPSTF and ACOG recommend screening for depression in pregnant and postpartum women at least once during the perinatal period. Women with risk factors (history of depression, anxiety, or previous postpartum depression) should be screened earlier and more frequently. The EPDS can also be administered during pregnancy for antenatal depression screening.

Q: What does a cutoff score of ≥10 mean?

A cutoff score of ≥10 on the EPDS indicates a positive screen for possible postpartum depression. At this cutoff, the EPDS has a sensitivity of approximately 80% and specificity of approximately 88% for major depressive disorder. Scores of 10-12 suggest possible depression requiring further assessment. Scores of ≥13 indicate probable depression of varying severity and warrant clinical evaluation and intervention. However, clinical judgment should always be used — a woman with a score below 10 but significant clinical concerns should still be evaluated further.

Q: What should I do if item 10 (self-harm) is positive?

Any score >0 on item 10 requires immediate safety assessment. This is a psychiatric emergency. Do not leave the patient alone. Assess current suicidal ideation, plan, intent, means, and protective factors. Ensure immediate psychiatric consultation. Create a safety plan and remove access to lethal means. Arrange for appropriate level of care (outpatient with frequent follow-up, partial hospitalization, or inpatient admission depending on risk level). Inform the patient's partner or family member if clinically appropriate and with consent.

📚Evidence-Based References

[1]
Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry. 1987;150:782-786.PubMed (3651732)
[2]
National Institute for Health and Care Excellence. Antenatal and postnatal mental health: clinical management and service guidance (CG192). NICE; 2014 (updated 2020).
[3]
American College of Obstetricians and Gynecologists. Screening for Perinatal Depression. ACOG Committee Opinion No. 757. Obstet Gynecol. 2018;132(5):e208-e212.
[4]
US Preventive Services Task Force. Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2023;329(24):2168-2179.PubMed (37338872)
Call Us
WhatsApp